NASDAQ · DGX
Healthcare · Medical - Diagnostics & Research
$247.08
Down-$0.43 (-0.17%)
Updated Sep 16, 2026, 4:50 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DGX closed at $247.08 after 20 trading sessions, up 4.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $238.39 | $248.65 | $237.21 | $247.08 | 1.37M |
| Sep 14, 2026 | $237.49 | $239.78 | $234.67 | $237.89 | 974.85K |
| Sep 11, 2026 | $233.20 | $235.12 | $229.33 | $235.02 | 997.03K |
| Sep 10, 2026 | $236.32 | $236.475 | $228.57 | $231.14 | 1.09M |
| Sep 9, 2026 | $233.58 | $236.24 | $232.43 | $235.46 | 791.15K |
| Sep 8, 2026 | $233.61 | $237.555 | $231.524 | $235.50 | 728.94K |
| Sep 4, 2026 | $235.38 | $238.915 | $235.38 | $237.14 | 798.7K |
| Sep 3, 2026 | $242.00 | $242.00 | $236.35 | $239.40 | 1.04M |
| Sep 2, 2026 | $238.03 | $242.835 | $236.27 | $240.80 | 1.14M |
| Sep 1, 2026 | $242.72 | $243.72 | $235.625 | $236.22 | 813.39K |
| Aug 31, 2026 | $241.99 | $242.635 | $239.40 | $240.30 | 1.36M |
| Aug 28, 2026 | $245.17 | $245.28 | $242.27 | $242.76 | 639.94K |
| Aug 27, 2026 | $242.83 | $247.19 | $242.44 | $244.61 | 839.99K |
| Aug 26, 2026 | $244.11 | $246.00 | $243.485 | $245.00 | 811.02K |
| Aug 25, 2026 | $243.93 | $245.78 | $241.79 | $244.51 | 709.15K |
| Aug 24, 2026 | $243.97 | $246.00 | $242.455 | $243.87 | 837.74K |
| Aug 21, 2026 | $240.33 | $244.70 | $239.43 | $244.39 | 1.26M |
| Aug 20, 2026 | $239.86 | $245.675 | $237.525 | $241.30 | 1.14M |
| Aug 19, 2026 | $238.10 | $242.39 | $237.38 | $241.76 | 924.01K |
| Aug 18, 2026 | $238.01 | $239.38 | $236.07 | $236.25 | 693.61K |
The latest Smart Investors Daily articles mentioning DGX.
DGX research
Company profile and research snapshot.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | UBS | Neutral | — |
| Jul 28, 2026 | JP Morgan | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | Baird | Neutral | — |
| Jul 24, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.
Yahoo · Sep 8, 2026
J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
Benzinga · Sep 8, 2026
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.
Yahoo · Sep 5, 2026
Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DGX.
